All In Biotech

Drug Trial Radar · NCT06812988

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of Brivekimig, a Dual Anti-TNF-α and Anti-OX40L NANOBODY® Molecule, for Preservation of Pancreatic β-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes

Last checked: Nov 19, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Feb 28, 2025

Primary completion

Apr 29, 2027

Study completion Apr 29, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study. The goal of this Phase 2a study is to assess safety and efficacy of brivekimig in comparison to placebo to preserve β-cell function in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) on insulin therapy. The study design comprises 2 parts: in Part A adult participants (18 to 35 years of age at screening) and in Part B adolescent and young adult participants (age range 12 to 21 years) will be randomized into brivekimig and placebo groups. Approximately 84 participants will be included with randomization ratio 3:1 (active:placebo). The study includes a screening period (3 to 5 weeks), a double-blind treatment period of 52 weeks and a safety follow-up of 26 weeks.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • BrivekimigDrug

    Pharmaceutical form: Solution Route of administration: Subcutaneous injection

  • PlaceboDrug

    Pharmaceutical form: Solution Route of administration: Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to Week 26 in mean 2-hour mixed meal tolerance test (MMTT) stimulated C-peptide concentrationTime frame: From Baseline to Week 26

Locations

24 sites in 8 countries. Site status is shown where the registry gives one.

  • Atlanta Diabetes Associates- Site Number : 8400006

    Atlanta, Georgia

  • IACT Health - Columbus - Talbotton Road- Site Number : 8400012

    Columbus, Georgia

  • Profound Research - MHP - TriAtria- Site Number : 8400015

    Farmington Hills, Michigan

  • Tekton Research - McKinney- Site Number : 8400017

    McKinney, Texas

  • Advanced Research Institute - Odgen- Site Number : 8400007

    Ogden, Utah

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina

  • Investigational Site Number : 0320005

    Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Salta, Argentina

  • Investigational Site Number : 0360003

    Saint Leonards, New South Wales, Australia

  • Investigational Site Number : 0360002

    Brisbane, Queensland, Australia

  • Investigational Site Number : 0360001

    Parkville, Victoria, Australia

  • Centro de Pesquisas Clínicas - São Paulo- Site Number : 0760002

    São Paulo, Brazil

  • Centro de Diabetes Curitiba- Site Number : 0760005

    Curitiba, Paraná, Brazil

  • Investigational Site Number : 1240006

    Surrey, British Columbia, Canada

  • Investigational Site Number : 1240001

    Vancouver, British Columbia, Canada

  • Investigational Site Number : 1520004

    Concepción, Biobio, Chile

  • Investigational Site Number : 1520003

    Providencia, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 3760001

    Jerusalem, Israel

  • Investigational Site Number : 3760003

    Kefar Sava, Israel

  • Investigational Site Number : 3760002

    Ramat Gan, Israel

  • Investigational Site Number : 6820002

    Riyadh, Saudi Arabia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.